ArticleJournal of chemical information and modeling2026
Generative Artificial Intelligence Optimization of Albumin Binders: Coumarin and Fatty Acid Derivatives.
Article in Journal of chemical information and modeling, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Previously, we reported a dual combination based on 4-hydroxycoumarin and dodecanedioic acid that could synergistically bind to human serum albumin (HSA). However, optimizing this combination remains challenging and could often be guided by empirical selection and extensive experimental screening, which may limit the chemical diversity and suboptimal affinity. In this study, we established a systematic artificial intelligence framework that integrates computational optimization with wet-lab synthesis and experimental validation, enabling improvement of the dual combination while preserving the core chemotypes. We first trained a machine learning classifier on curated HSA binding data and used it as an external scoring function to guide reinforcement learning-driven scaffold decoration with LibINVENT, enabling goal-directed generation of coumarin derivatives and fatty acid derivatives. Candidate molecules were prioritized through multiparameter filtering and diversity-aware selection, followed by synthesis and experimental validation using surface plasmon resonance. The optimized representatives show nanomolar HSA binding and enhanced affinity compared to the original ligands. Molecular docking and molecular dynamics simulations further provide a mechanistic rationale for the affinity improvements by revealing additional stabilizing interactions and more favorable binding energetics at the corresponding HSA sites. Besides, the optimized coumarin derivative (CD1) is a warfarin-derived coumarin analogue, yet it did not show detectable anticoagulant activity in an acute clotting time assay, whereas warfarin did. Overall, this work demonstrates a practical AI-guided route to expand chemical diversity and improve affinity for a synergistic HSA binding combination.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.